[1] Ferro JM, Aguiar de Sousa D. Cerebral venous thrombosis:an update[J]. Curr Neurol Neurosci Rep, 2019, 19:74. [2] Silvis SM, de Sousa DA, Ferro JM, Coutinho JM. Cerebral venous thrombosis[J]. Nat Rev Neurol, 2017, 13:555-565. [3] Ruuskanen JO, Kytö V, Posti JP, Rautava P, Sipilä JOT. Cerebral venous thrombosis:finnish nationwide trends[J]. Stroke, 2021, 52:335-338. [4] Otite FO, Patel S, Sharma R, Khandwala P, Desai D, Latorre JG, Akano EO, Anikpezie N, Izzy S, Malik AM, Yavagal D, Khandelwal P, Chaturvedi S. Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States[J]. Neurology, 2020, 95:e2200-2213. [5] Kowoll CM, Kaminski J, Weiβ V, Bösel J, Dietrich W, Jüttler E, Flechsenhar J, Guenther A, Huttner HB, Niesen WD, Pfefferkorn T, Schirotzek I, Schneider H, Liebig T, Dohmen C. Severe cerebral venous and sinus thrombosis:clinical course, imaging correlates, and prognosis[J]. Neurocrit Care, 2016, 25:392-399. [6] Yang X, Wu F, Liu Y, Duan J, Meng R, Chen J, Li D, Fan Z, Fisher M, Yang Q, Ji X. Predictors of successful endovascular treatment in severe cerebral venous sinus thrombosis[J]. Ann Clin Transl Neurol, 2019, 6:755-761. [7] Stam J, Majoie CB, van Delden OM, van Lienden KP, Reekers JA. Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis:a prospective study[J]. Stroke, 2008, 39:1487-1490. [8] Spadaro A, Scott KR, Koyfman A, Long B. Cerebral venous thrombosis:diagnosis and management in the emergency department setting[J]. Am J Emerg Med, 2021, 47:24-29. [9] Afifi K, Bellanger G, Buyck PJ, Zuurbier SM, Esperon CG, Barboza MA, Costa P, Escudero I, Renard D, Lemmens R, Hinteregger N, Fazekas F, Conde JJ, Giralt-Steinhauer E, Hiltunen S, Arauz A, Pezzini A, Montaner J, Putaala J, Weimar C, Schlamann M, Gattringer T, Tatlisumak T, Coutinho JM, Demaerel P, Thijs V. Features of intracranial hemorrhage in cerebral venous thrombosis[J]. J Neurol, 2020, 267:3292-3298. [10] Wang L, Duan J, Bian T, Meng R, Wu L, Zhang Z, Zhang X, Wang C, Ji X. Inflammation is correlated with severity and outcome of cerebral venous thrombosis[J]. J Neuroinflammation, 2018, 15:329. [11] Ding J, Song B, Xie X, Li X, Chen Z, Wang Z, Pan L, Lan D, Meng R. Inflammation in Cerebral Venous Thrombosis[J]. Front Immunol, 2022, 13:833490. [12] Röther J, Waggie K, van Bruggen N, de Crespigny AJ, Moseley ME. Experimental cerebral venous thrombosis:evaluation using magnetic resonance imaging[J]. J Cereb Blood Flow Metab, 1996, 16:1353-1361. [13] Nagai M, Terao S, Yilmaz G, Yilmaz CE, Esmon CT, Watanabe E, Granger DN. Roles of inflammation and the activated protein C pathway in the brain edema associated with cerebral venous sinus thrombosis[J]. Stroke, 2010, 41:147-152. [14] Ding R, Ou W, Chen C, Liu Y, Li H, Zhang X, Chai H, Ding X, Wang Q. Endoplasmic reticulum stress and oxidative stress contribute to neuronal pyroptosis caused by cerebral venous sinus thrombosis in rats:involvement of TXNIP/peroxynitrite-NLRP3 inflammasome activationρ[J]. Neurochem Int, 2020, 141:104856. [15] Rashad S, Niizuma K, Sato-Maeda M, Fujimura M, Mansour A, Endo H, Ikawa S, Tominaga T. Early BBB breakdown and subacute inflammasome activation and pyroptosis as a result of cerebral venous thrombosis[J]. Brain Res, 2018, 1699:54-68. [16] Gu JJ, Chen JB, Zhang JH, Zhang H, Wang SS. Recombinant human soluble thrombomodulin protects against brain injury in a CVST rat model, via downregulation of the HMGB1-RAGE axis[J]. Mol Med Rep, 2016, 14:5217-5222. [17] Mu SW, Dang Y, Fan YC, Zhang H, Zhang JH, Wang W, Wang SS, Gu JJ. Effect of HMGB1 and RAGE on brain injury and the protective mechanism of glycyrrhizin in intracranial-sinus occlusion followed by mechanical thrombectomy recanalization[J]. Int J Mol Med, 2019, 44:813-822. [18] Tiwari HS, Misra UK, Kalita J, Mishra A, Shukla S. Oxidative stress and glutamate excitotoxicity contribute to apoptosis in cerebral venous sinus thrombosis[J]. Neurochem Int, 2016, 100:91-96. Mishra DP, Kalita J, Misra UK. A [19] Tiwari HS, Tripathi AK, study of ER stress in rat model of cerebral venous sinus thrombosis[J]. Neurosci Lett, 2015, 589:121-125. [20] Wang L, Hauenstein AV. The NLRP3 inflammasome:mechanism of action, role in disease and therapies[J]. Mol Aspects Med, 2020, 76:100889. [21] Duan J, Leng X, Han Z, Cai Y, Wang C, Rajah G, Song H, Ding Y, Ji X. Identifying biomarkers associated with venous infarction in acute/subacute cerebral venous thrombosis[J]. Aging Dis, 2021, 12:93-101. [22] Aguiar de Sousa D, Pereira-Santos MC, Serra-Caetano A, Lucas Neto L, Sousa AL, Gabriel D, Correia M, Gil-Gouveia R, Oliveira R, Penas S, Carvalho Dias M, Correia MA, Carvalho M, Sousa AE, Canhão P, Ferro JM. Blood biomarkers associated with inflammation predict poor prognosis in cerebral venous thrombosis:a multicenter prospective observational study[J]. Eur J Neurol, 2021, 28:202-208. [23] Sassi SB, Touati N, Baccouche H, Drissi C, Romdhane NB, Hentati F. Cerebral venous thrombosis:a tunisian monocenter study on 160 patients[J]. Clin Appl Thromb Hemost, 2017, 23:1005-1009. [24] Gogu AE, Jianu DC, Dumitrascu V, Ples H, Stroe AZ, Docu Axelerad D, Docu Axelerad A. MTHFR gene polymorphisms and cardiovascular risk factors, clinical-imagistic features and outcome in cerebral venous sinus thrombosis[J]. Brain Sci, 2020, 11:23. M, Bucciarelli P, Gianniello F, [25] Artoni A, Abbattista Scalambrino E, Pappalardo E, Peyvandi F, Martinelli I. Platelet to lymphocyte ratio and neutrophil to lymphocyte ratio as risk factors for venous thrombosis[J]. Clin Appl Thromb Hemost, 2018, 24:808-814. [26] Dias L, Pinto MJ, Castro P, Carvalho M. Inflammatory biomarkers correlate with time evolution in cerebral venous thrombosis[J]. J Stroke Cerebrovasc Dis, 2021, 30:105844. [27] Zhang X, Ding R, Li H, Liu Y, Ou W, Hu J, Tian Y, Wang Q. An association between inflammation and cerebral venous thrombosis:a retrospective study[J]. J Stroke Cerebrovasc Dis, 2021, 30:106084. [28] Karahan SZ, Gazioglu S, Dilaver I, Boz C. The role of thrombo-inflammatory biomarkers in the prognosis of cerebral venous sinus thrombosis[J]. Curr Neurovasc Res, 2021, 18:237-243. [29] Li S, Liu K, Gao Y, Zhao L, Zhang R, Fang H, Tao Y, Liu H, Zhao J, Xia Z, Xu Y, Song B. Prognostic value of systemic immune-inflammation index in acute/subacute patients with cerebral venous sinus thrombosis[J]. Stroke Vasc Neurol, 2020, 5:368-373. [30] Song Q, Pan R, Jin Y, Wang Y, Cheng Y, Liu J, Wu B, Liu M. Correction to:lymphocyte-to-monocyte ratio and risk of hemorrhagic transformation in patients with acute ischemic stroke[J]. Neurol Sci, 2021, 42:765. [31] Li S, Liu K, Zhang R, Gao Y, Fang H, Liu X, Pei L, Chou LR, Guan S, Guo X, Xu H, Song B, Xu Y. Lower lymphocyte to monocyte ratio is a potential predictor of poor outcome in patients with cerebral venous sinus thrombosis[J]. Stroke Vasc Neurol, 2018, 4:148-153. [32] Iadecola C, Anrather J. The immunology of stroke:from mechanisms to translation[J]. Nat Med, 2011, 17:796-808. [33] Zhou Y, Wang Y, Wang J, Anne Stetler R, Yang QW. Inflammation in intracerebral hemorrhage:from mechanisms to clinical translation[J]. Prog Neurobiol, 2014, 115:25-44. [34] Fu Y, Liu Q, Anrather J, Shi FD. Immune interventions in stroke[J]. Nat Rev Neurol, 2015, 11:524-535. [35] Kamtchum-Tatuene J, Jickling GC. Blood biomarkers for stroke diagnosis and management[J]. Neuromolecular Med, 2019, 21:344-368. [36] Ning J, Duan JG, Ji XM. Severe cerebral venous sinus thrombosis with venous intracerebral hemorrhage:one case report[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2018, 18:813-817.[宁军, 段建钢, 吉训明. 伴静脉性脑出血的重症颅内静脉窦血栓形成一例[J]. 中国现代神经疾病杂志, 2018, 18:813-817.] [37] Coutinho JM, Zuurbier SM, Bousser MG, Ji X, Canhão P, Roos YB, Crassard I, Nunes AP, Uyttenboogaart M, Chen J, Emmer BJ, Roosendaal SD, Houdart E, Reekers JA, van den Berg R, de Haan RJ, Majoie CB, Ferro JM, Stam J; TO-ACT investigators. Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis:the TO-ACT randomized clinical trial[J]. JAMA Neurol, 2020, 77:966-973. Xiao LP, Ji XM. Feasibility of [38] Zhao TY, Duan JG, glucocorticoid for severe cerebral venous sinus thrombosis[J]. Hua Xi Yi Xue, 2020, 35:642-645.[赵婷玉, 段建钢, 肖立坡, 吉训明. 糖皮质激素治疗重症颅内静脉窦血栓形成的可行性探索[J]. 华西医学, 2020, 35:642-645.] |